Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity
ASSAY and Drug Development Technologies · 01.04.2021 · 19 (3) · 156-175
DOI: 10.1089/adt.2020.1014 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASSAY and Drug Development Technologies, erschienen am 01.04.2021. Verfasst von A Alper Öztürk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 106 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
- Department of Pharmaceutical Technology, Graduate School of Health Sciences, Anadolu University, Eskişehir, Turkey.
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Çukurova University, Adana, Turkey.
Zitieren
APA
Alper Öztürk, A., Namlı, İ., & Aygül, A. (2021). Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. ASSAY and Drug Development Technologies, 19(3), 156-175. https://doi.org/10.1089/adt.2020.1014
Vancouver
Alper Öztürk A, Namlı İ, Aygül A. Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. ASSAY and Drug Development Technologies. 2021;19(3):156-175. doi:10.1089/adt.2020.1014
BibTeX
@article{Alperztrk2021,
author = {Alper Öztürk, A and Namlı, İrem and Aygül, Abdurrahman},
title = {Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity},
journal = {ASSAY and Drug Development Technologies},
year = {2021},
volume = {19},
number = {3},
pages = {156--175},
doi = {10.1089/adt.2020.1014}
}
EUVIMED